Pub Date : 2025-12-01DOI: 10.1016/j.idnow.2025.105204
A. Raffetin , F. Roblot , C. Lenormand , Y. Hansmann , E. Baux , S. Nguala , P. Tattevin , C. Sobas , H. Yssel , A. Gautier , P. Arias , K. Bouiller
The aim of the clinical practice guideline is to support healthcare professionals in the diagnosis and management of patients with proven or suspected Lyme borreliosis (LB). The guideline provides an evidence-based algorithm for antibiotic therapy in confirmed LB cases and outlines recommendations for complex presentations where the three diagnostic criteria are not fully met, suggesting a possible challenge antibiotic therapy in specialized settings. Updated in accordance with international literature and previous French recommendations (HAS, 2022), the guidelines detail antibiotic selection and treatment duration according to clinical manifestations. Doxycycline remains the first-line treatment in most situations, including for children under eight years and pregnant or breastfeeding women. Treatment duration varies from 10 to 28 days depending on disease presentation: 10 days for isolated erythema migrans, 14 days for multiple erythema migrans or early neuroborreliosis, 21 days for lymphocytoma or late neuroborreliosis, and 28 days for Lyme arthritis or acrodermatitis chronica atrophicans. Longer treatments are not justified. In complex or recurrent cases, referral to a reference center is recommended. The guideline discourages the use of anti-inflammatory drugs in acute LB management and notes that corticosteroids do not worsen Lyme-related peripheral facial palsy. European treatment recommendations remain largely consistent across countries.
{"title":"Guidelines for Lyme borreliosis: treatment","authors":"A. Raffetin , F. Roblot , C. Lenormand , Y. Hansmann , E. Baux , S. Nguala , P. Tattevin , C. Sobas , H. Yssel , A. Gautier , P. Arias , K. Bouiller","doi":"10.1016/j.idnow.2025.105204","DOIUrl":"10.1016/j.idnow.2025.105204","url":null,"abstract":"<div><div>The aim of the clinical practice guideline is to support healthcare professionals in the diagnosis and management of patients with proven or suspected Lyme borreliosis (LB). The guideline provides an evidence-based algorithm for antibiotic therapy in confirmed LB cases and outlines recommendations for complex presentations where the three diagnostic criteria are not fully met, suggesting a possible challenge antibiotic therapy in specialized settings. Updated in accordance with international literature and previous French recommendations (HAS, 2022), the guidelines detail antibiotic selection and treatment duration according to clinical manifestations. Doxycycline remains the first-line treatment in most situations, including for children under eight years and pregnant or breastfeeding women. Treatment duration varies from 10 to 28 days depending on disease presentation: 10 days for isolated erythema migrans, 14 days for multiple erythema migrans or early neuroborreliosis, 21 days for lymphocytoma or late neuroborreliosis, and 28 days for Lyme arthritis or acrodermatitis chronica atrophicans. Longer treatments are not justified. In complex or recurrent cases, referral to a reference center is recommended. The guideline discourages the use of anti-inflammatory drugs in acute LB management and notes that corticosteroids do not worsen Lyme-related peripheral facial palsy. European treatment recommendations remain largely consistent across countries.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 8","pages":"Article 105204"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145632769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.idnow.2025.105203
Benoit Jaulhac , Kevin Bouiller , Cédric Lenormand , Elisabeth Baux , Jacques Sevestre , Aude Gautier , Chantal Sobas , Alice Raffetin
The diagnosis of Lyme borreliosis (LB) relies primarily on clinical evaluation supported by appropriate serologic testing in selected cases. Serology is recommended only in suspected disseminated LB, characterized by compatible clinical signs and history of tick exposure. In early localized disease such as erythema migrans, laboratory testing is unnecessary due to low sensitivity and the reliability of clinical diagnosis. A two-tiered testing algorithm remains the standard: enzyme-linked immunosorbent assay (ELISA) followed by immunoblot confirmation when ELISA results are positive or equivocal. For patients with symptoms lasting less than six weeks and negative initial results, serology should be repeated after three weeks. Only IgG are considered to confirm LB diagnosis. Intrathecal antibody synthesis is critical for diagnosing Lyme neuroborreliosis (LNB), achieving > 99 % sensitivity after 6–8 weeks, although isolated antibody index elevation without pleocytosis suggests alternative etiologies. Interpretation of serology must always consider clinical context: IgG may remain for years after recovery, and isolated IgM beyond six weeks typically represents a false positive. Serologic limitations include low sensitivity in early disease and cross-reactivity, particularly for IgM. PCR may aid diagnosis from synovial fluid or skin lesions but is rarely informative for cerebrospinal fluid. Emerging biomarkers such as CXCL13 and advanced molecular approaches remain experimental and require further validation.
{"title":"Guidelines for Lyme borreliosis: Diagnostic strategies","authors":"Benoit Jaulhac , Kevin Bouiller , Cédric Lenormand , Elisabeth Baux , Jacques Sevestre , Aude Gautier , Chantal Sobas , Alice Raffetin","doi":"10.1016/j.idnow.2025.105203","DOIUrl":"10.1016/j.idnow.2025.105203","url":null,"abstract":"<div><div>The diagnosis of Lyme borreliosis (LB) relies primarily on clinical evaluation supported by appropriate serologic testing in selected cases. Serology is recommended only in suspected disseminated LB, characterized by compatible clinical signs and history of tick exposure. In early localized disease such as erythema migrans, laboratory testing is unnecessary due to low sensitivity and the reliability of clinical diagnosis. A two-tiered testing algorithm remains the standard: enzyme-linked immunosorbent assay (ELISA) followed by immunoblot confirmation when ELISA results are positive or equivocal. For patients with symptoms lasting less than six weeks and negative initial results, serology should be repeated after three weeks. Only IgG are considered to confirm LB diagnosis. Intrathecal antibody synthesis is critical for diagnosing Lyme neuroborreliosis (LNB), achieving > 99 % sensitivity after 6–8 weeks, although isolated antibody index elevation without pleocytosis suggests alternative etiologies. Interpretation of serology must always consider clinical context: IgG may remain for years after recovery, and isolated IgM beyond six weeks typically represents a false positive. Serologic limitations include low sensitivity in early disease and cross-reactivity, particularly for IgM. PCR may aid diagnosis from synovial fluid or skin lesions but is rarely informative for cerebrospinal fluid. Emerging biomarkers such as CXCL13 and advanced molecular approaches remain experimental and require further validation.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 8","pages":"Article 105203"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.idnow.2025.105202
Elisabeth Baux , Yves Hansmann , Christine Tranchant , France Roblot , Pauline Arias , Benoît Jaulhac , Mathie Lorrot , Carole Eldin , Pierre Tattevin , Hans Yssel , Steve Nguala , Aude Gautier , Cédric Lenormand , Alice Raffetin
Lyme borreliosis (LB) is a tick-borne zoonosis caused by spirochetes belonging to the Borrelia burgdorferi sensu lato (Bb sl) complex. In Europe, multiple pathogenic species—including B. afzelii, B. garinii, and B. burgdorferi sensu stricto—are responsible for a wide diversity of clinical manifestations. The disease may present in various stages—localized, early disseminated, or late disseminated—depending on the time elapsed since the tick bite and the organs involved, such as the skin, joints, or nervous system.
Erythema migrans (EM) is the most frequent clinical presentation, accounting for approximately 80 % of LB cases in France. It is an early localized form, characterized by a painless, centrifugally expanding erythematous lesion centered on the tick-bite site, typically appearing 3 to 30 days post-exposure and resolving within 15 days under antibiotic therapy. Neuroborreliosis (NBL), most commonly associated with B. garinii, occurs in approximately 6–15 % of French cases. It represents a disseminated form, often presenting as meningoradiculitis or peripheral facial palsy, with generally favorable outcomes under antibiotic treatment, although persistent post-infectious symptoms may occur.
These guidelines address the full clinical spectrum of LB, from common manifestations such as EM to rare complications involving cardiac or ophthalmological systems. They also encompass atypical presentations not specifically linked to LB and provide specific recommendations for special populations, including pregnant women and immunocompromised patients. The current section summarizes the principal clinical features of LB and supports the rationale underlying recent diagnostic and therapeutic recommendations.
{"title":"Guidelines for Lyme borreliosis: clinical manifestations","authors":"Elisabeth Baux , Yves Hansmann , Christine Tranchant , France Roblot , Pauline Arias , Benoît Jaulhac , Mathie Lorrot , Carole Eldin , Pierre Tattevin , Hans Yssel , Steve Nguala , Aude Gautier , Cédric Lenormand , Alice Raffetin","doi":"10.1016/j.idnow.2025.105202","DOIUrl":"10.1016/j.idnow.2025.105202","url":null,"abstract":"<div><div>Lyme borreliosis (LB) is a tick-borne zoonosis caused by spirochetes belonging to the <em>Borrelia burgdorferi</em> sensu lato (Bb sl) complex. In Europe, multiple pathogenic species—including <em>B. afzelii</em>, <em>B. garinii</em>, and <em>B. burgdorferi</em> sensu stricto—are responsible for a wide diversity of clinical manifestations. The disease may present in various stages—localized, early disseminated, or late disseminated—depending on the time elapsed since the tick bite and the organs involved, such as the skin, joints, or nervous system.</div><div>Erythema migrans (EM) is the most frequent clinical presentation, accounting for approximately 80 % of LB cases in France. It is an early localized form, characterized by a painless, centrifugally expanding erythematous lesion centered on the tick-bite site, typically appearing 3 to 30 days post-exposure and resolving within 15 days under antibiotic therapy. Neuroborreliosis (NBL), most commonly associated with <em>B. garinii</em>, occurs in approximately 6–15 % of French cases. It represents a disseminated form, often presenting as meningoradiculitis or peripheral facial palsy, with generally favorable outcomes under antibiotic treatment, although persistent post-infectious symptoms may occur.</div><div>These guidelines address the full clinical spectrum of LB, from common manifestations such as EM to rare complications involving cardiac or ophthalmological systems. They also encompass atypical presentations not specifically linked to LB and provide specific recommendations for special populations, including pregnant women and immunocompromised patients. The current section summarizes the principal clinical features of LB and supports the rationale underlying recent diagnostic and therapeutic recommendations.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 8","pages":"Article 105202"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.idnow.2025.105205
P. Arias , X. Gocko , F. Roblot , Y. Hansmann , E. Baux , C. Eldin , S. Nguala , A. Gautier , C. Lemogne , A. Raffetin
Persistent symptoms following appropriate treatment of confirmed Lyme borreliosis (LB) require a systematic clinical reassessment. The diagnostic approach should verify the accuracy of the initial diagnosis, adherence to and adequacy of antibiotic therapy, and consider potential sequelae or differential diagnoses such as new-onset diseases or comorbidities. When no alternative explanation is found, symptoms may correspond to Post-Treatment Lyme Disease Syndrome (PTLDS), as defined by the French National Authority for Health (HAS). PTLDS is characterized by fatigue, diffuse pain, and cognitive dysfunction lasting more than six months after a documented and adequately treated LB episode. The syndrome significantly impairs daily functioning and quality of life and is not attributable to persistent infection or other identifiable causes. Management relies on long-term, multidisciplinary, and personalized care coordinated between reference centers and primary physicians, focusing on physical rehabilitation and psychological support. Additional antibiotic or immunomodulatory therapies are not recommended due to lack of efficacy and potential adverse effects. Future research should prioritize high-quality clinical studies to clarify therapeutic indications, integrate social science perspectives to better understand the illness and its controversies, and actively involve patients to ensure that research and care strategies align with their lived experiences.
{"title":"Guidelines for Lyme borreliosis: post-treatment Lyme disease syndrome (PTLDS)","authors":"P. Arias , X. Gocko , F. Roblot , Y. Hansmann , E. Baux , C. Eldin , S. Nguala , A. Gautier , C. Lemogne , A. Raffetin","doi":"10.1016/j.idnow.2025.105205","DOIUrl":"10.1016/j.idnow.2025.105205","url":null,"abstract":"<div><div>Persistent symptoms following appropriate treatment of confirmed Lyme borreliosis (LB) require a systematic clinical reassessment. The diagnostic approach should verify the accuracy of the initial diagnosis, adherence to and adequacy of antibiotic therapy, and consider potential sequelae or differential diagnoses such as new-onset diseases or comorbidities. When no alternative explanation is found, symptoms may correspond to Post-Treatment Lyme Disease Syndrome (PTLDS), as defined by the French National Authority for Health (HAS). PTLDS is characterized by fatigue, diffuse pain, and cognitive dysfunction lasting more than six months after a documented and adequately treated LB episode. The syndrome significantly impairs daily functioning and quality of life and is not attributable to persistent infection or other identifiable causes. Management relies on long-term, multidisciplinary, and personalized care coordinated between reference centers and primary physicians, focusing on physical rehabilitation and psychological support. Additional antibiotic or immunomodulatory therapies are not recommended due to lack of efficacy and potential adverse effects. Future research should prioritize high-quality clinical studies to clarify therapeutic indications, integrate social science perspectives to better understand the illness and its controversies, and actively involve patients to ensure that research and care strategies align with their lived experiences.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 8","pages":"Article 105205"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145632723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-29DOI: 10.1016/j.idnow.2025.105220
Mickael Manchon , Mallorie Kerjouan , Delphine Bachelet , Stéphane Jouneau , Charles Ricordel , Cédric Laouenan , Nathalie De Castro , Pierre Tattevin
Introduction
Failure to achieve sputum culture conversion after two months of treatment (M2) for pulmonary tuberculosis (TB) is associated with treatment failure. We aimed to identify the determinants of persistent culture-positive sputum at M2.
Methods
We performed an ancillary study of the multicentric randomized trial FAST-TB, which enrolled adult patients with smear-positive rifampicin-susceptible pulmonary TB in France in 2014–2018.
Results
Among the 203 patients enrolled in the FAST-TB study, 177 were evaluated at M2, including 104 with sputum culture: 82 (79 %) culture-negative, and 22 (21 %) culture-positive. Persistence of cough and sputum during follow-up was associated with culture positivity at M2: This was significant for sputum at different time points (respectively 84 % in culture-positive vs. 50 % in culture-negative at M1, 65 % vs. 37 % at M2, and 43 % vs. 17 % at M4, P < 0.05 for all), and for persistent cough at M4 (71 %, vs. 36 %, P = 0.006). Treatment success was similar between groups.
Conclusion
The main predictors of culture-positive sputum at M2 in patients with smear-positive rifampicin-susceptible pulmonary TB are persistent cough and sputum during treatment. Systematic monitoring of these symptoms could contribute to early detection of patients who may require prolonged anti-TB treatment.
{"title":"Factors predicting 2-month culture positivity in smear-positive pulmonary tuberculosis","authors":"Mickael Manchon , Mallorie Kerjouan , Delphine Bachelet , Stéphane Jouneau , Charles Ricordel , Cédric Laouenan , Nathalie De Castro , Pierre Tattevin","doi":"10.1016/j.idnow.2025.105220","DOIUrl":"10.1016/j.idnow.2025.105220","url":null,"abstract":"<div><h3>Introduction</h3><div>Failure to achieve sputum culture conversion after two months of treatment (M2) for pulmonary tuberculosis (TB) is associated with treatment failure. We aimed to identify the determinants of persistent culture-positive sputum at M2.</div></div><div><h3>Methods</h3><div>We performed an ancillary study of the multicentric randomized trial FAST-TB, which enrolled adult patients with smear-positive rifampicin-susceptible pulmonary TB in France in 2014–2018.</div></div><div><h3>Results</h3><div>Among the 203 patients enrolled in the FAST-TB study, 177 were evaluated at M2, including 104 with sputum culture: 82 (79 %) culture-negative, and 22 (21 %) culture-positive. Persistence of cough and sputum during follow-up was associated with culture positivity at M2: This was significant for sputum at different time points (respectively 84 % in culture-positive vs. 50 % in culture-negative at M1, 65 % vs. 37 % at M2, and 43 % vs. 17 % at M4, P < 0.05 for all), and for persistent cough at M4 (71 %, vs. 36 %, <em>P</em> = 0.006). Treatment success was similar between groups.</div></div><div><h3>Conclusion</h3><div>The main predictors of culture-positive sputum at M2 in patients with smear-positive rifampicin-susceptible pulmonary TB are persistent cough and sputum during treatment. Systematic monitoring of these symptoms could contribute to early detection of patients who may require prolonged anti-TB treatment.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 1","pages":"Article 105220"},"PeriodicalIF":2.2,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-29DOI: 10.1016/j.idnow.2025.105218
Aqeela malik , Fatima Ali , Waseem Safdar , Muhammad Tariq Saeed , Muhammad Tariq Navid , Farheen Ansari
Introduction
Human parainfluenza virus type 4b (HPIV-4b) is an under-recognized but clinically significant pathogen associated with acute respiratory tract infections (ARTIs), particularly in young children. Its molecular and epidemiological profiles remain poorly characterized in resource-limited Pakistani settings. This study aimed to investigate the prevalence, clinical associations, and molecular characteristics of HPIV-4b among children under five years of age presenting with respiratory illnesses in the Cholistan region of Pakistan.
Patients and Methods
Between October 2022 and March 2025, 200 nasopharyngeal swabs were collected from pediatric patients exhibiting respiratory symptoms. Samples were screened for HPIV-4b using multiplex reverse transcriptase PCR (mRT-PCR). Positive samples were subjected to further molecular analysis of the hemagglutinin-neuraminidase (HN) and fusion (F) genes. Selected strains underwent sequencing and phylogenetic analysis.
Results
HPIV-4b was detected in 80 (40 %) of the children, with the highest positivity observed in infants aged 0–1 year. A higher infection rate was noted in male children (62.5 %). Clinical features associated with infection included fever, barking cough, and wheezing (p < 0.05). The virus was more prevalent among children from socioeconomically disadvantaged families and those with a family history of pulmonary disorders. Sequence data revealed high similarity between local strains and international isolates from Japan, the USA, and China. Phylogenetic analysis indicated the circulation of genetically distinct but evolutionarily conserved HPIV-4b lineages.
Conclusion
This is the first molecular and epidemiological characterization of HPIV-4b in Pakistani children, highlighting its clinical relevance and genetic diversity. The findings underscore a need for early diagnosis and sustained genomic monitoring.
{"title":"Molecular and epidemiological characterization of human parainfluenza virus Type 4b in children with respiratory illnesses in Cholistan, Pakistan","authors":"Aqeela malik , Fatima Ali , Waseem Safdar , Muhammad Tariq Saeed , Muhammad Tariq Navid , Farheen Ansari","doi":"10.1016/j.idnow.2025.105218","DOIUrl":"10.1016/j.idnow.2025.105218","url":null,"abstract":"<div><h3>Introduction</h3><div>Human parainfluenza virus type 4b (HPIV-4b) is an under-recognized but clinically significant pathogen associated with acute respiratory tract infections (ARTIs), particularly in young children. Its molecular and epidemiological profiles remain poorly characterized in resource-limited Pakistani settings. This study aimed to investigate the prevalence, clinical associations, and molecular characteristics of HPIV-4b among children under five years of age presenting with respiratory illnesses in the Cholistan region of Pakistan.</div></div><div><h3>Patients and Methods</h3><div>Between October 2022 and March 2025, 200 nasopharyngeal swabs were collected from pediatric patients exhibiting respiratory symptoms. Samples were screened for HPIV-4b using multiplex reverse transcriptase PCR (mRT-PCR). Positive samples were subjected to further molecular analysis of the hemagglutinin-neuraminidase (HN) and fusion (F) genes. Selected strains underwent sequencing and phylogenetic analysis.</div></div><div><h3>Results</h3><div>HPIV-4b was detected in 80 (40 %) of the children, with the highest positivity observed in infants aged 0–1 year. A higher infection rate was noted in male children (62.5 %). Clinical features associated with infection included fever, barking cough, and wheezing (p < 0.05). The virus was more prevalent among children from socioeconomically disadvantaged families and those with a family history of pulmonary disorders. Sequence data revealed high similarity between local strains and international isolates from Japan, the USA, and China. Phylogenetic analysis indicated the circulation of genetically distinct but evolutionarily conserved HPIV-4b lineages.</div></div><div><h3>Conclusion</h3><div>This is the first molecular and epidemiological characterization of HPIV-4b in Pakistani children, highlighting its clinical relevance and genetic diversity. The findings underscore a need for early diagnosis and sustained genomic monitoring.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 1","pages":"Article 105218"},"PeriodicalIF":2.2,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Profile of HIV resistance to antiretrovirals in children born to HIV-positive mothers on dolutegravir in Togo from 2021 to 2023","authors":"Kokou Tegueni , Arnold Junior Sadio , Laetitia Serrano , Mounerou Salou , Martine Peeters , Didier Koumavi Ekouevi , Claver Anoumou Dagnra","doi":"10.1016/j.idnow.2025.105221","DOIUrl":"10.1016/j.idnow.2025.105221","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 1","pages":"Article 105221"},"PeriodicalIF":2.2,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-27DOI: 10.1016/j.idnow.2025.105216
É. Piet , F. Bastides , J. Leporrier , O. Robineau , É. Estrabaud , V. Pourcher , L. Slama
Background
Complementarily to immuno-virological control of people living with HIV (PLWH), quality of life (QoL) has become a priority in patient care.
Methods
OCTAVE® is a self-administered questionnaire comprising 42 questions categorized in eight items: HIV treatment, mental & physical health, sleep, sexuality, emotional well-being, comorbidities and social/professional life. It was developed for use in routine clinical practice, the objective being to identify possible QoL alterations in people living with HIV.
Outcomes
Thirty-nine physicians completed the survey, and 380 PLWH filled out the self-administered questionnaire. All in all, QoL alterations were detected in 44 % of respondents (mean 2.1 (SD = 1.2) per PLWH). For physicians, these findings prompted planned clinical interventions in 70 % of PLWH, predominantly regarding sleep, sexual health and emotional well-being. Of note, 11 % of the reported QoL alterations were attributed to antiretroviral therapy.
Conclusion
In routine clinical practice OCTAVE®, appears to be an effective means of detecting QoL impairments in people living with HIV, and it is likely to reinforce clinical management of potential QoL issues.
{"title":"Detecting quality of life alterations in people living with HIV: Development and evaluation of the OCTAVE® self-questionnaire","authors":"É. Piet , F. Bastides , J. Leporrier , O. Robineau , É. Estrabaud , V. Pourcher , L. Slama","doi":"10.1016/j.idnow.2025.105216","DOIUrl":"10.1016/j.idnow.2025.105216","url":null,"abstract":"<div><h3>Background</h3><div>Complementarily to immuno-virological control of people living with HIV (PLWH), quality of life (QoL) has become a priority in patient care.</div></div><div><h3>Methods</h3><div>OCTAVE® is a self-administered questionnaire comprising 42 questions categorized in eight items: HIV treatment, mental & physical health, sleep, sexuality, emotional well-being, comorbidities and social/professional life. It was developed for use in routine clinical practice, the objective being to identify possible QoL alterations in people living with HIV.</div></div><div><h3>Outcomes</h3><div>Thirty-nine physicians completed the survey, and 380 PLWH filled out the self-administered questionnaire. All in all, QoL alterations were detected in 44 % of respondents (mean 2.1 (SD = 1.2) per PLWH). For physicians, these findings prompted planned clinical interventions in 70 % of PLWH, predominantly regarding sleep, sexual health and emotional well-being. Of note, 11 % of the reported QoL alterations were attributed to antiretroviral therapy.</div></div><div><h3>Conclusion</h3><div>In routine clinical practice OCTAVE®, appears to be an effective means of detecting QoL impairments in people living with HIV, and it is likely to reinforce clinical management of potential QoL issues.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 2","pages":"Article 105216"},"PeriodicalIF":2.2,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145632743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号